572 related articles for article (PubMed ID: 27651838)
1. Epigenetic modulators as therapeutic targets in prostate cancer.
Graça I; Pereira-Silva E; Henrique R; Packham G; Crabb SJ; Jerónimo C
Clin Epigenetics; 2016; 8():98. PubMed ID: 27651838
[TBL] [Abstract][Full Text] [Related]
2. Epigenetic Modulators as Therapeutic Agents in Cancer.
Patnaik E; Madu C; Lu Y
Int J Mol Sci; 2023 Oct; 24(19):. PubMed ID: 37834411
[TBL] [Abstract][Full Text] [Related]
3. Epigenetic therapy in urologic cancers: an update on clinical trials.
Faleiro I; Leão R; Binnie A; de Mello RA; Maia AT; Castelo-Branco P
Oncotarget; 2017 Feb; 8(7):12484-12500. PubMed ID: 28036257
[TBL] [Abstract][Full Text] [Related]
4. New clinical developments in histone deacetylase inhibitors for epigenetic therapy of cancer.
Cang S; Ma Y; Liu D
J Hematol Oncol; 2009 Jun; 2():22. PubMed ID: 19486511
[TBL] [Abstract][Full Text] [Related]
5. Dual inhibitors of HDAC and other epigenetic regulators: A novel strategy for cancer treatment.
Shirbhate E; Singh V; Jahoriya V; Mishra A; Veerasamy R; Tiwari AK; Rajak H
Eur J Med Chem; 2024 Jan; 263():115938. PubMed ID: 37989059
[TBL] [Abstract][Full Text] [Related]
6. Fluctuations of Histone Chemical Modifications in Breast, Prostate, and Colorectal Cancer: An Implication of Phytochemicals as Defenders of Chromatin Equilibrium.
Samec M; Liskova A; Koklesova L; Mestanova V; Franekova M; Kassayova M; Bojkova B; Uramova S; Zubor P; Janikova K; Danko J; Samuel SM; Büsselberg D; Kubatka P
Biomolecules; 2019 Dec; 9(12):. PubMed ID: 31817446
[TBL] [Abstract][Full Text] [Related]
7. State-of-the-art in transposable element modulation affected by drugs in malignant prostatic cancer cells.
Terrazzan A; Vanini R; Ancona P; Bianchi N; Taccioli C; Aguiari G
J Cell Biochem; 2024 May; 125(5):e30557. PubMed ID: 38501160
[TBL] [Abstract][Full Text] [Related]
8. Epigenetic modulating agents as a new therapeutic approach in multiple myeloma.
Maes K; Menu E; Van Valckenborgh E; Van Riet I; Vanderkerken K; De Bruyne E
Cancers (Basel); 2013 Apr; 5(2):430-61. PubMed ID: 24216985
[TBL] [Abstract][Full Text] [Related]
9. Transcending frontiers in prostate cancer: the role of oncometabolites on epigenetic regulation, CSCs, and tumor microenvironment to identify new therapeutic strategies.
Ambrosini G; Cordani M; Zarrabi A; Alcon-Rodriguez S; Sainz RM; Velasco G; Gonzalez-Menendez P; Dando I
Cell Commun Signal; 2024 Jan; 22(1):36. PubMed ID: 38216942
[TBL] [Abstract][Full Text] [Related]
10. The pharmacoepigenetic paradigm in cancer treatment.
Ocaña-Paredes B; Rivera-Orellana S; Ramírez-Sánchez D; Montalvo-Guerrero J; Freire MP; Espinoza-Ferrao S; Altamirano-Colina A; Echeverría-Espinoza P; Ramos-Medina MJ; Echeverría-Garcés G; Granda-Moncayo D; Jácome-Alvarado A; Andrade MG; López-Cortés A
Front Pharmacol; 2024; 15():1381168. PubMed ID: 38720770
[TBL] [Abstract][Full Text] [Related]
11. Genetic and epigenetic changes in human prostate cancer.
Koochekpour S
Iran Red Crescent Med J; 2011 Feb; 13(2):80-98. PubMed ID: 22737441
[TBL] [Abstract][Full Text] [Related]
12. MT-EpiPred: Multitask Learning for Prediction of Small-Molecule Epigenetic Modulators.
Zhang R; Xie X; Ni D; Wang H; Li J; Xiao W
J Chem Inf Model; 2024 Jan; 64(1):110-118. PubMed ID: 38109786
[TBL] [Abstract][Full Text] [Related]
13. Clinical Application of Circulating Tumour Cells in Prostate Cancer: From Bench to Bedside and Back.
León-Mateos L; Vieito M; Anido U; López López R; Muinelo Romay L
Int J Mol Sci; 2016 Sep; 17(9):. PubMed ID: 27657044
[TBL] [Abstract][Full Text] [Related]
14. Prostate Cancer: Epigenetic Alterations, Risk Factors, and Therapy.
Kgatle MM; Kalla AA; Islam MM; Sathekge M; Moorad R
Prostate Cancer; 2016; 2016():5653862. PubMed ID: 27891254
[TBL] [Abstract][Full Text] [Related]
15. Current therapeutic options targeting bone metastasis in metastatic castration resistant prostate cancer.
Fragkoulis C; Gkialas I; Papadopoulos G; Ntoumas K
J BUON; 2016; 21(4):787-791. PubMed ID: 27685897
[TBL] [Abstract][Full Text] [Related]
16. Prognostic Utility of a New mRNA Expression Signature of Gleason Score.
Sinnott JA; Peisch SF; Tyekucheva S; Gerke T; Lis R; Rider JR; Fiorentino M; Stampfer MJ; Mucci LA; Loda M; Penney KL
Clin Cancer Res; 2017 Jan; 23(1):81-87. PubMed ID: 27663590
[TBL] [Abstract][Full Text] [Related]
17. A Phase II Trial of Abiraterone Combined with Dutasteride for Men with Metastatic Castration-Resistant Prostate Cancer.
McKay RR; Werner L; Mostaghel EA; Lis R; Voznesensky O; Zhang Z; Marck BT; Matsumoto AM; Domachevsky L; Zukotynski KA; Bhasin M; Bubley GJ; Montgomery B; Kantoff PW; Balk SP; Taplin ME
Clin Cancer Res; 2017 Feb; 23(4):935-945. PubMed ID: 27683182
[No Abstract] [Full Text] [Related]
18. Androgen receptor-dependent and -independent mechanisms driving prostate cancer progression: Opportunities for therapeutic targeting from multiple angles.
Hoang DT; Iczkowski KA; Kilari D; See W; Nevalainen MT
Oncotarget; 2017 Jan; 8(2):3724-3745. PubMed ID: 27741508
[TBL] [Abstract][Full Text] [Related]
19. Epigenetics in Cancer: A Hematological Perspective.
Stahl M; Kohrman N; Gore SD; Kim TK; Zeidan AM; Prebet T
PLoS Genet; 2016 Oct; 12(10):e1006193. PubMed ID: 27723796
[TBL] [Abstract][Full Text] [Related]
20. Exploitation of Castration-Resistant Prostate Cancer Transcription Factor Dependencies by the Novel BET Inhibitor ABBV-075.
Faivre EJ; Wilcox D; Lin X; Hessler P; Torrent M; He W; Uziel T; Albert DH; McDaniel K; Kati W; Shen Y
Mol Cancer Res; 2017 Jan; 15(1):35-44. PubMed ID: 27707886
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
